Coronavirus (COVID-19) vaccination rates among adults who live in England, including estimates by socio-demographic characteristic and Standard Occupational Classification (SOC) 2020

Age-standardised mortality rates for deaths involving coronavirus (COVID-19), non-COVID-19 deaths and all deaths by vaccination status, broken down by age group.

The data source for this dataset is the NI Vaccine Management System (VMS). VMS holds vaccination reports for COVID-19 and influenza vaccines which were either administered in NI or to NI residents. This dataset is an aggregated summary of COVID-19 vaccinations recorded in VMS. It is effectively a day-by-day count of living people vaccinated by dose, age band (on the day that the dataset was extracted from VMS) and LGD of residence. Aggregated summary data from VMS is published daily to the NI COVID-19 Vaccinations Dashboard. This dataset is updated weekly and allows NI vaccination coverage to be included in the GOV.UK Coronavirus (COVID-19) in the UK dashboard.

Vaccination rates and odds ratios by socio-demographic group among people living in England.

United Kingdom UK: Immunization: Measles: % of Children Aged 12-23 Months data was reported at 92.000 % in 2017. This stayed constant from the previous number of 92.000 % for 2016. United Kingdom UK: Immunization: Measles: % of Children Aged 12-23 Months data is updated yearly, averaging 86.500 % from Dec 1980 (Median) to 2017, with 38 observations. The data reached an all-time high of 93.000 % in 2015 and a record low of 53.000 % in 1980. United Kingdom UK: Immunization: Measles: % of Children Aged 12-23 Months data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s United Kingdom – Table UK.World Bank.WDI: Health Statistics. Child immunization, measles, measures the percentage of children ages 12-23 months who received the measles vaccination before 12 months or at any time before the survey. A child is considered adequately immunized against measles after receiving one dose of vaccine.; ; WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).; Weighted average;

The number of COVID-19 vaccination doses administered per 100 people in the United Kingdom rose to 224 as of Oct 27 2023. This dataset includes a chart with historical data for the United Kingdom Coronavirus Vaccination Rate.

Covid vaccinations administered by local area since 8th December 2020. It includes the calculated percentage of the 12+ population who have received all required vaccinations and/or boosters.Population estimates are based on National Immunisation Management Service counts.

Antibody data, by UK country and age, from the Coronavirus (COVID-19) Infection Survey.

The number and percentage of Covid-19 fully vaccinated people by age band. Population estimates are based on National Immunisation Management Service counts.This dataset has been updated to reflect new age bandings and population figures provided in July 2022.This dataset now includes details of the Autumn Booster programme.Note on analysis:This datasets presents the proportion of the eligible population who have received all vaccinations they are entitled to. This is terms as a "Complete Dose". The number of vaccinations required to qualify as a complete dose differs by the age of the individual. The following scale is used to determine this:- Aged 5 - 15 - Dose 1- Aged 16 - 24 - Dose 1 & Dose 2- Aged 35 - 50 - Dose 1, Dose 2 & Booster- Aged 50+ - Dose1, Dose2, Booster & Autumn BoosterData is updated weekly.

Estimates of the risk of all-cause and cardiac death in the 12 weeks after vaccination or positive SARS-CoV-2 test compared with subsequent weeks for people aged 12 to 29 years in England using two sources of mortality data: ONS death registrations and deaths recorded in Hospital Episode Statistics. 8 December 2020 to 25 May 2022. Experimental Statistics.

Flu vaccine uptake (%) in children aged 2 to 3 years old, who received the flu vaccination between 1st September to the end of February as recorded in the GP record. The February collection has been adopted for our end of season figures from 2017 to 2018. All previous data is the same definitions but until the end of January rather than February to consider data returning from outside the practice and later in practice vaccinations.RationaleInfluenza (also known as Flu) is a highly infectious viral illness spread by droplet infection. The flu vaccination is offered to people who are at greater risk of developing serious complications if they catch the flu. The seasonal influenza programme for England is set out in the Annual Flu Letter. Both the flu letter and the flu plan have the support of the Chief Medical Officer (CMO), Chief Pharmaceutical Officer (CPhO), and Director of Nursing.Vaccination coverage is the best indicator of the level of protection a population will have against vaccine-preventable communicable diseases. Immunisation is one of the most effective healthcare interventions available, and flu vaccines can prevent illness and hospital admissions among these groups of people. Increasing the uptake of the flu vaccine among these high-risk groups should also contribute to easing winter pressure on primary care services and hospital admissions. Coverage is closely related to levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise.The UK Health Security Agency (UKHSA) will continue to provide expert advice and monitoring of public health, including immunisation. NHS England now has responsibility for commissioning the flu programme, and GPs continue to play a key role. NHS England teams will ensure that robust plans are in place locally and that high vaccination uptake levels are reached in the clinical risk groups. For more information, see the Green Book chapter 19 on Influenza.The Annual flu letter sets out the national vaccine uptake ambitions each year. In 2021 to 2022, the national ambition was to achieve at least 70% vaccine uptake in those aged 2 to 3 years old. Prior to this, the national vaccine uptake ambition was 75% in line with WHO targets.Definition of numeratorNumerator is the number of vaccinations administered during the influenza season between 1st September and the end of February.Definition of denominatorDenominator is the GP registered population on the date of extraction including patients who have been offered the vaccine but refused it, as the uptake rate is measured against the overall eligible population. For more detailed information please see the user guide, available to view and download from https://www.gov.uk/government/collections/vaccine-uptake#seasonal-flu-vaccine-uptakeCaveatsThis collection has received approval from the Data Coordination Board (DCB).Data is final and represents a percentage of all GP practices in England responding to the final survey. Where a total for England is quoted (e.g., a sum of the number of patients registered and number vaccinated), this is taken from the GP practice sample and is therefore not an extrapolated figure.For definitions of clinical at-risk groups for those aged 6 months to under 65 years, see the annual flu letter published at Annual Flu Programme.The age under 65 clinical at-risk group data includes pregnant women with other risk factors but excludes otherwise 'healthy' pregnant women and carers.All figures are derived from data as extracted from records on GP systems or as submitted by GP practices, Area Teams, and CCGs.Data source: ImmForm website: registered patient GP practice data, Influenza Immunisation Vaccine Uptake Monitoring Programme, OHID.

Figures on coronavirus (COVID-19) vaccine uptake in school pupils aged 12 to 17 years attending state-funded secondary, sixth form and special schools, broken down by demographic and geographic characteristics, using a linked English Schools Census and National Immunisation Management System dataset. Experimental Statistics.

UK: Immunization: HepB3: % of One-Year-Old Children data was reported at 93.000 % in 2019. UK: Immunization: HepB3: % of One-Year-Old Children data is updated yearly, averaging 93.000 % from Dec 2019 (Median) to 2019, with 1 observations. UK: Immunization: HepB3: % of One-Year-Old Children data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s United Kingdom – Table UK.World Bank.WDI: Health Statistics. Child immunization rate, hepatitis B is the percentage of children ages 12-23 months who received hepatitis B vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized after three doses.; ; WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).; Weighted average;

Children for whom the local authority is responsible who completed a booster course of diphtheria, tetanus, pertussis, polio (DTaP and IPV) vaccine at any time by their fifth birthday as a percentage of all children whose fifith birthday falls within the time period.RationaleA booster vaccine for diphtheria, tetanus, pertusiss and polio disease has been in the routine childhood immunisation programme since late 2001. It is currently offered at 3 year and 4 months or soon after. Vaccination coverage is the best indicator of the level of protection a population will have against vaccine preventable communicable diseases. Coverage is closely correlated with levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise. Previous evidence shows that highlighting vaccination programmes encourages improvements in uptake levels. May also have relevance for NICE guidance PH21: Reducing differences in the uptake of immunisations (The guidance aims to increase immunisation uptake among those aged under 19 years from groups where uptake is low).Definition of numeratorNumber of children in LA responsible population whose fifth birthday falls within the time period who received a DTaP and IPV booster at any time before their fifth birthday.Definition of denominatorTotal number of children in LA responsible population whose fifth birthday falls within the time period. Coverage figures are supplied for patients registered with GPs based in that LA and for unregistered patients who were resident in that LA. The LA responsible population is therefore different from the estimated resident population figures produced by the Office of National Statistics (ONS) for each LA. For the COVER collection, the LA responsible population is usually derived from the population registers held on CHISs.CaveatsFull GP postcodes are used to aggregate data to ICB. The GP-level coverage data is collected by NHS Digital Strategic Data Collection Service (SDCS) and published by the UK Health Security Agency (UKHSA) COVER team. ICB data is experimental and should be treated with caution as it is not an official statistic.Information on childhood immunisation coverage at ages one, two, and five is collected through the UK COVER collection by UKHSA. These aggregated data are collected from CHISs, computerised systems storing clinical records that support health promotion and prevention activities for children, including immunisation. In England, COVER data are collected for Upper Tier Local Authorities (LAs) using the COVER data collection form. These are established collections based on total populations, not samples.The number of CHIS systems has decreased from over 100 in 2015 to around 70 by mid-2017. As different phases of the digital strategy are implemented across the country, it is anticipated that there may be further temporary local data quality issues associated with the transition. Temporary data quality issues in some London COVER returns during 2017 to 2018 were observed in the quarterly COVER reports as the new Hubs became responsible for generating coverage data. Changes in vaccine coverage within London should therefore be interpreted with caution for the time being.Data are extracted directly from local population registers, and data issues are generally related to underestimation of coverage. There may be some overestimation of denominators due to children who have moved away remaining on the area register, which can lead to underestimates of coverage. In some areas, it is known that a small number of GPs do not submit vaccination data to the local CHIS, also resulting in underestimation of coverage. Using non-standardised data extraction methods could result in overestimated coverage.Caution should be exercised when comparing coverage figures over time due to occasional data quality issues reported by some data suppliers. Apparent trends could reflect changes in the quality of data reported as well as real changes in vaccination coverage. While this issue will be more apparent at the local level, it may also impact national figures. Similarly, some caution should be exercised when comparing coverage between different areas where data quality issues have been reported.

All children at age 12 months who have received the complete course (3 doses) of hepatitis B vaccine within each reporting area as a percentage of all the eligible population as defined in the hepatitis B chapter of the immunisation against infectious diseases "Green Book" (have maternal Hep B positive status).RationaleInfants born to hepatitis B virus (HBV) infected mothers are at high risk of acquiring HBV infection themselves. Babies born to infected mothers are given a dose of the hepatitis B vaccine after they are born. This is followed by another two doses (with a month in between each) and a booster dose 12 months later. Around 20% of people with chronic hepatitis B will go on to develop scarring of the liver (cirrhosis), which can take 20 years to develop, and around 1 in 10 people with cirrhosis will develop liver cancer.Vaccination coverage is the best indicator of the level of protection a population will have against vaccine preventable communicable diseases. Coverage is closely correlated with levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise.Since April 2000 it has been recommended that all pregnant women in England and Wales should be offered testing for hepatitis B through screening for HBsAg, and that all babies of HBsAg seropositive women should be immunised (HSC 1998 127). A dose of paediatric hepatitis B vaccine is recommended for all infants born to an HBV infected mother as soon as possible after birth, then at 1 and 2, and 12 months of age ( https://www.gov.uk/government/collections/hepatitis-b-guidance-data-and-analysis ). Previous evidence shows that highlighting vaccination programmes encourages improvements in uptake levels may also have relevance for NICE guidance PH21: Reducing differences in the uptake of immunisations (The guidance aims to increase immunisation uptake among those aged under 19 years from groups where uptake is low).Definition of numeratorNumber of children at age 12 months who have received the complete course (3 doses) of hepatitis B vaccine. Numerator counts for local authorities include all people registered with practices in the local authority, and no data are available to provide resident based figures.Definition of denominatorEligible population as defined in the hepatitis B chapter of the immunisation against infectious diseases "Green Book" (have maternal Hep B positive status).Denominators for local authorities include all people registered with practices in the local authority, and no data are available to provide resident based figures.CaveatsThese statistics have been published as ‘experimental statistics’ in the NHS Digital “NHS Immunisation Statistics, England” report. There are a number of issues with the hepatitis B dataset which have either impacted on data quality or have raised potential concerns around the quality of the data. Selective neonatal hepatitis B coverage data are reported by local authority (LA) responsible population for the first time in the 2015 to 2016 publication. Many LAs could not supply complete data on infants born to hepatitis B positive mothers and for a number of other LAs there were data quality issues. It has therefore not been possible to estimate figures for those LAs or describe the quality/completeness of LA data with any accuracy. (see Quality Statement for 2015 to 2016 for more information). Office of Health Improvement and Disparities has also published data for LAs that are co terminus with former PCTs but provided data by PCT rather than LA. These data were not published or validated by NHS Digital.

All children for whom the local authority is responsible who received one dose of MMR on or after their first birthday and at any time up to their second birthday as a percentage of all children whose second birthday falls within the time period.RationaleMMR is the combined vaccine that protects against measles, mumps and rubella. Measles, mumps and rubella are highly infectious, common conditions that can have serious complications, including meningitis, swelling of the brain (encephalitis) and deafness. They can also lead to complications in pregnancy that affect the unborn baby and can lead to miscarriage.Vaccination coverage is the best indicator of the level of protection a population will have against vaccine preventable communicable diseases. Coverage is closely correlated with levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise.The first MMR vaccine is given to children as part of the routine vaccination schedule, usually within a month of their first birthday. They'll then have a booster dose before starting school, which is usually between three and five years of age. Previous evidence shows that highlighting vaccination programmes encourages improvements in uptake levels.May also have relevance for NICE guidance PH21: Reducing differences in the uptake of immunisations (The guidance aims to increase immunisation uptake among those aged under 19 years from groups where uptake is low).Definition of numeratorTotal number of children whose second birthday falls within the time period who received one dose of MMR on or after their first birthday and at any time before their second birthday.Data for 2013 to 2014 are available at source at LA level. Data prior to 2013 to 2014 were collected at PCT level and converted to LA level using the criteria as described in the notes section below.Definition of denominatorTotal number of children whose second birthday falls within the time period.Data from 2013to 2014 are available at source at LA level. Data prior to 2013 to 2014 were collected at PCT level and converted to LA level using the criteria as described in the notes section below.CaveatsFull GP postcodes are used to aggregate data to ICB. The GP-level coverage data is collected by NHS Digital Strategic Data Collection Service (SDCS) and published by the UK Health Security Agency (UKHSA) COVER team. ICB data is experimental data and should be treated with caution. It is not an official statistic.

https://www.gov.uk/vaccine-damage-payment/if-you-disagree-with-a-decision

These data describe pneumococcal polysaccharide vaccine (PPV) uptake for the survey year, for those aged 65 years and over.RationaleVaccination coverage is the best indicator of the level of protection a population will have against vaccine preventable communicable diseases. Coverage is closely related to levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise. Pneumococcal disease is a significant cause of morbidity and mortality. Certain groups are at risk for severe pneumococcal disease, these include young children, the elderly and people who are in clinical risk groups2. Pneumococcal infections can be non invasive such as bronchitis, otitis media or invasive such as septicaemia, pneumonia, meningitis. Cases of invasive pneumococcal infection usually peak in the winter during December and January. The pneumococcal polysaccharide vaccine (PPV) protects against 23 types of Streptococcus pneumoniae bacterium. It is thought that the PPV is around 50 percent to 70 percent effective at preventing more serious types of invasive pneumococcal infection2.Since 1992 the 23 valent PPV has been recommended for people in the clinical risk groups and since 2003, the PPV vaccination programme has expanded to include immunisation to all those aged 65 years and over in England1This indicator was judged to be a valid and an important measure of public health and was therefore included in the public health outcomes framework. Inclusion of these indicators will encourage the continued prioritisation and evaluation and the effectiveness of the PPV vaccination programme and give an indication of uptake at an upper tier Local Authority level. The vaccination surveys measure the proportion of eligible people that have received PPV at any time and the proportion that received PPV during the previous year, providing an opportunity to assess the delivery of the immunisation programme11 Pneumococcal Polysaccharide Vaccine (PPV) coverage report, England, April 2013 to March 2014 [online]. 2015 [cited 2015 Mar]. Available from URL: https://www.gov.uk/government/publications/pneumococcal-polysaccharide-vaccine-ppv-vaccine-coverage-estimates 2 Pneumococcal infections, NHS Choices [online]. 2013 [cited 2013 Dec]. Available from URL: http://www.nhs.uk/conditions/vaccinations/pages/pneumococcal-vaccination.aspxDefinition of numeratorUKHSA provided UTLA level data. Clinical commissioning group (CCG) data is available from https://www.gov.uk/government/collections/vaccine-uptake#ppv-vaccine-uptakeDefinition of denominatorNumber of adults aged 65 years and over. Data from 2013 to 2014 are now available at source at a local authority level. Data prior to 2013 to 2014 were collected at a PCT level and converted to LA level for inclusion in PHOF using the criteria as defined below:Denominators for local authorities are estimated from denominators for PCTs. Denominators for PCTs include all people registered with practices accountable to the PCT, and no data are available to provide resident-based figures. Denominators for local authorities are estimated as follows: (For local authorities that have exactly the same boundary as a PCT, the PCT figure is used as it is the only estimate available for the residents of the PCT and local authority. For local authorities whose boundary is contained wholly within a single PCT, but is not equal to the whole PCT, the LA denominator is estimated as a proportion of the PCT figure, with the exceptions of Isles of Scilly, City of London, Rutland, Cornwall, Hackney and Leicestershire (see below). For local authorities whose boundaries include all or part of more than one PCT, the local authority denominator is estimated by aggregating the appropriate proportions of the denominators for the PCTs whose boundaries include part of the local authority. The appropriate proportions in cases ii and iii are defined according to the resident population (in the appropriate age group) in the calendar year overlapping most of the period of the indicator value (or the most recent available): resident population by Lower Layer Super Output Area were extracted and used to calculate the population resident in every LA PCT overlapping block.To calculate the denominator, each LA PCT overlap is calculated as a proportion of the PCT resident population, and then multiplied by the denominator for the PCT. A LA may overlap several PCTs: the appropriate portions of all the PCTs’ denominators are aggregated to give the denominator estimate for the LA. Expressed as an equation the denominator is calculated as follows: DenominatorLA = ∑ (DenominatorPCT × n/N) summed over all PCTs overlapping the LA where: DenominatorLA = Estimated denominator in the LA n = Population resident in the LA-PCT overlapping block N = Population resident in the PCT DenominatorPCT = Denominator in the PCT For Isles of Scilly, City of London and Rutland, no indicator data are presented (prior to 2013 to 2014), as the local authority makes up a very small proportion of the PCT, and estimates for the LAs based on the PCT figures are unlikely to be representative as they are swamped by the much larger local authority within the same PCT. The estimates for Cornwall, Hackney and Leicestershire local authorities are combined data for Cornwall and Isles of Scilly, City of London and Hackney, and Leicestershire and Rutland respectively in order to ensure that all valid PCT data are included in the England total.Denominators for Cornwall and Isles of Scilly, City of London and Hackney, and Leicestershire and Rutland are not combined for the 2019 to 2020 annual local authority level data."CaveatsThe pneumococcal vaccine uptake collection is a snapshot of GP patients vaccinated currently registered at the time of data extraction. The proportion of GP practices who provided data for the surveys are available from the uptake reports. Data will exclude patients who have received the vaccine but have subsequently died, patients who have since moved, or patients that are vaccinated but have not had their electronic patient record updated by the time of data extraction. Data for local authorities prior to 2013 to 2014 have been estimated from registered PCT level indicators. While the majority of patients registered with practices accountable to a PCT tend to be resident within that PCT, there are, in some PCTs, significant differences between their resident and registered populations. Therefore the estimates for LAs may not always accurately reflect the resident population of the local authority (LA). Please note that the PCT response rate should be checked for data completeness as this will have a knock on effect to the LA values.

This dataset is no longer updated, find vaccination data here From 24 March 2022, Public Health Scotland (PHS) began reporting the number of people who have received a fourth dose of Covid-19 vaccination. Vaccine uptake statistics among care home residents and those who are severely immunosuppressed will be reported initially. PHS will include further updates as the Spring/Summer vaccination programme rolls out. In addition, as part of our continuous review of reporting, PHS made some changes to vaccine uptake statistics. From 24 March 2022, the deceased and those who no longer live in Scotland are no longer be included in vaccine uptake statistics. Historic trend data have been updated to take into account this new methodology for all apart from the Daily Trends by JCVI Priority Group table (more details about the data in this table are below). Scotland level data for all vaccinations administered (i.e. including those who have since died or moved from Scotland) are still available in the Daily Trend of All Vaccinations Delivered in Scotland table. Also from 24 March 2022, Dose 3/Booster doses are termed "Dose 3". To allow new data to be fully processed and available at 14:00, the Daily COVID-19 in Scotland and COVID-19 Vaccination in Scotland datasets will be temporarily unavailable from 12:45 to 14:00. During this window, the datasets will not be visible and any queries made to these datasets will return a 404 - Not found error. At all other times the datasets will be available in full as usual. PHS reviewed the JCVI priority group uptake figures from 18 November 2021, specifically how we derive the numerator and the denominator. The rational for the change is to ensure we report on most up to date living population for each group. For this, the list of individuals in each cohort has been refreshed to be more current. We have also removed individuals who have since died to reflect the current living population. From the 24 March 2022 those who are no longer living in Scotland have also been removed from the numerator and denominator for JCVI priority group uptake figures. This means all the JCVI cohorts and populations have changed for both numerator and denominators on these two dates and care should be taken when interpreting trends. On 08 December 2020, a Coronavirus (COVID-19) vaccine developed by Pfizer BioNTech (Comirnaty) was first used in the UK as part of national immunisation programmes. The AstraZeneca (Spikevax) vaccine was also approved for use in the national programme, and rollout of this vaccine began on 04 January 2021. Moderna (Vaxzevria) vaccine was approved for use on 8 January 2021 and rollout of this vaccine began on 07 April 2021. These vaccines have met strict standards of safety, quality and effectiveness set out by the independent Medicines and Healthcare Products Regulatory Agency (MHRA). Those giving the vaccine to others were the first to receive the vaccination. In the first phase of the programme, NHS Scotland followed the independent advice received from the Joint Committee on Vaccination and Immunisation (JCVI) and prioritised delivery of the vaccine to those with the greatest clinical need, in line with the recommended order of prioritisation. For booster vaccinations a similar approach has been adopted. Definitions used in the vaccine uptake by JCVI priority group resource can be found in the JCVI Priority Group Definitions table. Individuals can appear in more than one JCVI priority group. This dataset provides information on daily number of COVID vaccinations in Scotland. Data on the total number of vaccinations in Scotland is presented by day administered and vaccine type, by age group, by sex, by non-age cohorts and by geographies (NHS Board and Local Authority). As the population in the cohorts can change with time, these will be refined when updated data are available. Additional data sources relating to this topic area are provided in the Links section of the Metadata below. Data visualisation and additional notes are available on the Public Health Scotland - Covid 19 Scotland dashboard.

Children for whom the local authority is responsible who received 3 doses of DTaP IPV Hib HepB vaccine (Diphtheria, tetanus, pertussis/whooping cough, polio, Haemophilus influenzae type b and hepatitis B) at any time by their first birthday as a percentage of all children whose first birthday falls within the time period.RationaleThe combined DTaP IPV Hib HepB is the first in a course of vaccines offered to babies to protect them against diphtheria, pertussis (whooping cough), tetanus, Haemophilus influenzae type b (an important cause of childhood meningitis and pneumonia), polio (IPV is inactivated polio vaccine) and from 2019, Hepatitis B.Vaccination coverage is the best indicator of the level of protection a population will have against vaccine preventable communicable diseases. Coverage is closely correlated with levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise.The combined DTaP IPV Hib HepB is the first in a course of vaccines offered to babies to protect them against these six diseases. The vaccine is offered when babies are two, three and four months old. Previous evidence shows that highlighting vaccination programmes encourages improvements in uptake levels .May also have relevance for NICE guidance PH21: Reducing differences in the uptake of immunisations (The guidance aims to increase immunisation uptake among those aged under 19 years from groups where uptake is low).Definition of numeratorTotal number of children whose first birthday falls within the time period who received 3 doses of DTaP IPV Hib HepB at any time before their first birthday.Data for 2013 to 2014 are available at source at LA level.Data prior to 2013 to 2014 were collected at PCT level and converted to LA level using the criteria as described in the notes section below. From 2019/20, for the 12 month cohort, coverage reported is for the DTaP/IPV/Hib/HepB (6 in 1) vaccination, which replaced the DTaP/IPV/Hib (5 in 1) vaccination.Definition of denominatorTotal number of children whose first birthday falls within the time period.Data from 2013 to 2014 are available at source at LA level. Data prior to 2013 to 2014 were collected at PCT level and converted to LA level using the criteria as described in the notes section below.CaveatsFull GP postcodes are used to aggregate data to ICB. The GP-level coverage data is collected by NHS Digital Strategic Data Collection Service (SDCS) and published by the UK Health Security Agency (UKHSA) COVER team. ICB data is experimental data and should be treated with caution. It is not an official statistic.